H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in.

TheFly reported on April 29 that H.C. Wainwright increased its price objective for HALO to $95 from $90 and reiterated its Buy recommendation on the stock. The firm pointed to expectations of a first-quarter royalty reset and anticipates stronger royalty growth momentum for HALO beginning in the second quarter and continuing through the remainder of 2026. H.C. Wainwright noted that upcoming quarters could provide indications of improving royalty performance as the company advances its commercial and partnership-driven revenue streams.

In separate news, on May 6, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Oruka Therapeutics disclosed a worldwide exclusive partnership and licensing deal involving Halozyme’s wholly owned subsidiary, Halozyme Hypercon. Under the agreement, Oruka obtained rights to use HALO’s Hypercon technology for ORKA-001, which is being developed for psoriasis and other inflammatory conditions, with potential expansion to one additional therapeutic target.

H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook

Hypercon is designed as a microparticle-based system that enables higher drug concentration, lowering injection volumes, and improving ease of administration for patients. The deal includes an upfront payment from Oruka to HALO, along with the possibility of additional milestone-based payments in the future. HALO is also set to receive mid-single-digit royalty payments on net sales of any products developed using the licensed technology.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology company based in San Diego that specializes in oncology drug delivery. It is best known for its ENHANZE technology, which enables faster, high-volume subcutaneous drug administration and is widely licensed to pharmaceutical partners for cancer therapies.

While we acknowledge the risk and potential of HALO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HALO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now  and 9 Most Undervalued Healthcare Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.